Does Lacosamide Interact with Common Heart Medications?
Lacosamide, an anticonvulsant used for partial-onset seizures, can interact with heart medications, primarily through effects on heart rhythm and conduction. It carries FDA warnings for PR interval prolongation, atrioventricular block, and atrial fibrillation/flutter, increasing risks when combined with drugs that slow heart rate or affect cardiac conduction.[1][2]
Key interactions include:
- Beta-blockers (e.g., metoprolol, atenolol): Both prolong PR interval; combination raises risk of bradycardia or heart block. Monitor ECG and heart rate.[2][3]
- Calcium channel blockers (e.g., diltiazem, verapamil): Additive AV node suppression can lead to severe bradycardia or conduction delays.[2][4]
- Digoxin: Lacosamide may increase digoxin levels, heightening toxicity risks like arrhythmias.[3]
- Antiarrhythmics (e.g., amiodarone, flecainide): Potential for compounded QT prolongation or conduction issues.[2]
No major pharmacokinetic interactions via CYP enzymes, as lacosamide is minimally metabolized that way, but pharmacodynamic effects on the heart dominate concerns.[1]
What Do Clinical Studies and Labels Say?
Product labeling (Vimpat) advises caution or avoidance with drugs causing PR prolongation. A 2010 study in Epilepsia found lacosamide increased PR interval by 2-3 ms at therapeutic doses, more in patients with baseline conduction issues.[5] Post-marketing reports note rare second/third-degree AV block, especially with carbamazepine (not a heart drug but relevant for combo therapy).[1]
Prescribing info recommends baseline ECG, monitoring in elderly or heart disease patients, and dose adjustments.[2]
Who Should Avoid or Monitor Closely?
- Patients with sick sinus syndrome, second/third-degree AV block, or atrial fibrillation.
- Those on multiple cardiac meds—risk escalates with polypharmacy.
- Renal/hepatic impairment worsens effects, as lacosamide clearance drops.[1]
Consult a doctor for personalized checks; tools like Lexicomp or Micromedex flag specifics.[3]
Safer Alternatives for Seizure Control with Heart Issues?
Options like levetiracetam or lamotrigine have lower cardiac risk profiles. Levetiracetam shows no PR prolongation in studies.[6] Switch decisions depend on seizure type and comorbidities.
[1]: Vimpat (lacosamide) Prescribing Information
[2]: FDA Drug Safety Communication on Lacosamide
[3]: Lexicomp Drug Interactions: Lacosamide
[4]: Epilepsy Foundation: Lacosamide Cardiac Effects
[5]: Cawello W et al. Epilepsia. 2010;51(5):702-10. PubMed
[6]: Harden CL. Ther Adv Neurol Disord. 2010;3(2):49-58. PubMed